AG
LGND icon

Advisor Group’s Ligand Pharmaceuticals LGND Stock Holding History

Advisor Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$154K Sell
2,377
-1,105
-32% -$73.8K ﹤0.01% 2602
2019
Q3 		$217K Sell
3,482
-2,435
-41% -$153K ﹤0.01% 2261
2019
Q2 		$421K Buy
5,917
+133
+2% +$9.8K ﹤0.01% 1737
2019
Q1 		$454K Sell
5,784
-238
-4% -$18K ﹤0.01% 1662
2018
Q4 		$511K Sell
6,022
-4,617
-43% -$492K 0.01% 1394
2018
Q3 		$1.82M Sell
10,639
-119
-1% -$17.9K 0.02% 680
2018
Q2 		$1.39M Buy
10,758
+6,143
+133% +$685K 0.02% 708
2018
Q1 		$475K Buy
4,615
+2,879
+166% +$285K 0.01% 1356
2017
Q4 		$148K Sell
1,736
-13
-0.7% -$1.13K ﹤0.01% 2249
2017
Q3 		$149K Sell
1,749
-50
-3% -$3.96K ﹤0.01% 2079
2017
Q2 		$136K Sell
1,799
-93
-5% -$6.51K ﹤0.01% 2066
2017
Q1 		$125K Sell
1,892
-36
-2% -$2.37K ﹤0.01% 2014
2016
Q4 		$122K Sell
1,928
-4,604
-70% -$291K ﹤0.01% 1933
2016
Q3 		$416K Buy
6,532
+1,340
+26% +$98.4K 0.01% 1075
2016
Q2 		$385K Buy
+5,192
New +$385K 0.01% 1054

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Advisor Group's LGND Position: Q4 2019 in Review

Advisor Group reduced its Ligand Pharmaceuticals (LGND) stake by 32% in Q4 2019, selling an estimated $73.8K and leaving 2,377 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #2602.

Advisor Group first reported a position in LGND in Q2 2016 and has held it in 15 quarters since. The position peaked at $1.82M in Q3 2018. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

  • Advisor Group held 2,377 shares of Ligand Pharmaceuticals worth $154K as of Q4 2019.
  • Advisor Group sold 1,105 Ligand Pharmaceuticals shares in Q4 2019, an estimated $73.8K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2602 holding.
  • Advisor Group first reported a position in Ligand Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Ligand Pharmaceuticals position peaked at $1.82M in Q3 2018.
  • 266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.